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Abstract
Dependence on opioids and the number of opioid overdose deaths are serious and escalating public health
problems, but medication-assisted treatments for opioid addiction remain inadequate for many patients.
Glucagon-like pepide-1 (GLP-1) is a gut hormone and neuropeptide with actions in peripheral tissues and in
the brain, including regulation of blood glucose and food intake. GLP-1 analogs, which are approved
diabetes medications, can reduce the reinforcing and rewarding effects of alcohol, cocaine, amphetamine,
and nicotine in rodents. Investigations on effects of GLP-1 analogs on opioid reward and reinforcement have
not been reported. We assessed the effects of the GLP-1 receptor agonist Exendin-4 (Ex4) on opioid-related
behaviors in male mice, i.e., morphine-conditioned place preference (CPP), intravenous self-administration
(IVSA) of the short-acting synthetic opioid remifentanil, naltrexone-precipitated morphine withdrawal, mor-
phine analgesia (male and female mice), and locomotor activity. Ex4 treatment had no effect on morphine-
induced CPP, withdrawal, or hyperlocomotion. Ex4 failed to decrease remifentanil self-administration, if
anything reinforcing effects of remifentanil appeared increased in Ex4-treated mice relative to saline. Ex4
did not significantly affect analgesia. In contrast, Ex4 dose dependently decreased oral alcohol self-
administration, and suppressed spontaneous locomotor activity. Taken together, Ex4 did not attenuate the
addiction-related behavioral effects of opioids, indicating that GLP-1 analogs would not be useful medica-
tions in the treatment of opioid addiction. This difference between opioids and other drug classes investi-
gated to date may shed light on the mechanism of action of GLP-1 receptor treatment in the addictive effects
of alcohol, central stimulants, and nicotine.
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Significance Statement
Opioid overdoses are now the leading cause of death for age under 50 in the United States, and effective
new treatments to curb opioid addiction worldwide are urgently needed. Glucagon-like pepide-1 (GLP-1)
analogs are safe, approved, diabetes medications that have shown promising “anti-addiction” effects in
preclinical studies with alcohol, central stimulants, and nicotine. In the present study, we report that GLP-1
receptor stimulation does not attenuate rewarding or reinforcing effects of opioid drugs and does not
attenuate acquisition or expression of opioid withdrawal.
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Introduction
Opioid dependence is a still rapidly increasing public
health problem (Hedegaard et al., 2017, Seth et al., 2018).
Death by drug overdose has become the leading cause of
death for age under 50 in the United States (data are from
the Multiple Cause of Death Files, 1999–2016, as com-
piled from data provided by the 57 vital statistics jurisdic-
tions through the Vital Statistics Cooperative Program;
Centers for Disease Control and Prevention, National
Center for Health Statistics, 2017). The current treatment
options for opioid addiction are limited and they require
continuous daily monitoring by health professionals to be
safe and effective (Volkow et al., 2014; Volkow and Col-
lins, 2017). There is therefore an urgent need to address
the ongoing and worsening opioid epidemic and identify
better medication-assisted treatments. Glucagon-like
peptide-1 (GLP-1) is a polypeptide with both hormone
and neuropeptide functions. It is produced in the intestinal
system, where it is released in response to nutrient inges-
tion, as well as in the brain (Holst, 2013). GLP-1 decreases
food intake and body weight, and has homeostatic effects
on blood glucose by activating insulin secretion and de-
creasing glucagon secretion (Drucker et al., 2017). This
combination of effects makes GLP-1 receptor agonists
like Exendin-4 (Ex4; exenatide) an effective treatment for
type 2 diabetes, an indication for which they have been
used for over a decade (Eng et al., 2014; Andersen et al.,
2018).
GLP-1 receptors are expressed in peripheral tissues
like the pancreas, and in many brain regions, and GLP-1
regulates feeding behavior and food intake at least in part
through central mechanisms (Skibicka, 2013; Sisley et al.,
2014; van Bloemendaal et al., 2014). GLP-1 receptors are
also found in areas associated with reward, reinforce-
ment, and addiction including the ventral tegmental area
and nucleus accumbens (Göke et al., 1995; Merchentha-
ler et al., 1999; Alhadeff et al., 2012; Cork et al., 2015;
Heppner et al., 2015). In humans, gene variants of the
GLP-1 receptor are associated with increased prevalence
of alcohol use disorder and with increased responses to
alcohol in laboratory studies (Suchankova et al., 2015).
Diabetes patients treated with the GLP-1 analog liraglu-
tide reported decreases in alcohol intake (Kalra et al.,
2011). In rodents and non-human primates, systemic or
central administration of Ex4 and other GLP-1 receptor
agonists attenuate addiction-related effects of alcohol,
cocaine, amphetamine, and nicotine, including self-ad-
ministration/drinking, conditioned place preference (CPP),
and striatal dopamine efflux (Graham et al., 2013; Egecio-
glu et al., 2013a,b,c; Shirazi et al., 2013; Suchankova
et al., 2015; Sørensen et al., 2015, 2016; Reddy et al.,
2016; Vallöf et al., 2016; Fortin and Roitman, 2017; Tuesta
et al., 2017; Thomsen et al., 2017, 2018). Those findings
indicate that GLP-1 receptor stimulation modulates the
rewarding and reinforcing effects of drugs of abuse and
that GLP-1 receptor agonists represent a possible treat-
ment for addictions (Fink-Jensen and Vilsbøll, 2016). At
present, Ex4 is being evaluated in clinical trials for the
management of alcohol use disorder and for smoking
cessation, respectively (Antonsen et al., 2018; Yammine
et al., 2018). Despite these promising findings and the fact
that GLP-1 receptor agonists are already approved as
diabetes medications, making them easily available for
treatment of drugs and alcohol use disorders, the possi-
ble effects of GLP-1 receptor agonists on addiction-
related effects of opioids have not yet been reported.
Here, we tested GLP-1 receptor stimulation using
Ex4 on three abuse-related effects of opioid drugs: (1)
rewarding effects, using a CPP assay with morphine; (2)
the direct reinforcing effects, using intravenous self-
administration (IVSA) of the fast-onset short-duration opi-
oid agonist remifentanil (Panlilio and Schindler, 2000); (3)
dependence/withdrawal, using antagonist-precipitated
morphine withdrawal. The IVSA experiment included
transgenic knock-out (KO) mice lacking GLP-1 receptors
in the central nervous system selectively, following the
hypothesis that Ex4 would decrease remifentanil IVSA in
WT mice, but not in the KO mice. A secondary hypothesis
was that remifentanil IVSA would be increased in the KO
mice, because whole-body GLP-1 receptor KO mice were
reported to self-administer more nicotine and have stron-
ger cocaine-induced CPP than WT mice (Harasta et al.,
2015; Tuesta et al., 2017). Furthermore, because of the
clinical importance of opioids in pain management, we
investigated whether Ex4 treatment would interfere with
the therapeutic properties of morphine, an important con-
sideration if GLP-1 receptor agonists were to be used in
the treatment of addiction to opioids. For this we used a
hot-plate assay, which is thought to involve brain pro-
cessing, rather than a spinal reflex (Le Bars et al., 2001).
Finally, we verified the effectiveness of Ex4 using end-
points previously reported to be sensitive to GLP-1 recep-
tor stimulation, namely locomotor activity and oral alcohol
self-administration, measured in direct comparison to the
opioid assays.
Materials and Methods
Animals
Glp1rflox/flox nestin-Cre/ KO mice with a neuronal-
specific deletion of the GLP-1 receptor was generated as
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described by Sisley et al. (2014) and bred in the animal
facility at the Panum Institute, University of Copenhagen.
The Glp1rflox/flox nestin-Cre-/- littermates were used as
wild type (WT) controls, genotype was determined by
polymerase chain reaction on DNA extracted from ear clip
samples. Male C57BL/6NTac (B6) mice were acquired at
seven to eight weeks of age (Taconic, Denmark). All mice
were acclimated to the housing facilities at Laboratory of
Neuropsychiatry (AAALAC accredited) at least 7 d before
the experiments were initiated. Mice were kept on a re-
verse 12/12 h light/dark cycle under temperature and
humidity control, and all experiments were performed in
the dark phase. Tap water and regular rodent chow were
available ad libitum, mice were group housed up to eight per
cage with hiding devices, nesting material, and wooden chew-
ing block as enrichment. Procedures were approved by the
Animal Experiments Inspectorate under the Danish Ministry of
Food, Agriculture, and Fisheries in accordance with the Euro-
pean Union directive 2010/63/EU.
Apparatus
Behavioral studies were conducted in equipment from
Med Associates: mouse modular operant-conditioning
chambers (ENV-307A) for self-administration studies
(Thomsen and Caine, 2005; Thomsen et al., 2009), and
open field activity chambers (OFA 510) for place condi-
tioning studies (Dall et al., 2017). All chambers were indi-
vidually enclosed in sound-attenuating cubicles equipped
with a white light and a ventilation fan. The operant-
conditioning chambers contained two nose-poke holes
each fitted with a photocell and a yellow cue light, and a
low-torque liquid swivel (375/25; Instech Laboratories)
mounted on a balance arm was used for intravenous drug
delivery from a syringe pump in the freely moving animals.
The activity chambers for CPP were fitted with a beam-
break movement detection system. An unbiased two-
compartment design was used, with distinct floor materials
(metal wire grid vs gray plastic Lego plate) in the two com-
partments. For the hot-plate assay, a Hot Plate Analgesia
Meter (Harvard Apparatus) was used at 55  0.2°C, with a
floor consisting of a 10-mm aluminum plate, 20 cm in diam-
eter, enclosed by a clear plastic cylinder. In the withdrawal
assay clear plastic cylinders20 cm in diameter and 60 cm
tall were used for observation.
CPP and locomotor activity
Male B6 mice were used. Mice were habituated to the
test room for at least 60 min before the beginning of the
session. During pre-conditioning (day 1) and post-
conditioning test (day 10) mice were allowed to move
freely between the two compartments for 30 min. No
individual mice showed preference on the pre-condi-
tioning day as defined by 75% time spent on one side,
and mice showed no significant preference as a group.
During conditioning sessions (days 2–9), mice were con-
fined to the Lego or grid compartment for 40 min. The
mice were assigned to treatment in counterbalanced
groups after the pre-conditioning day based on their time
spent in the two compartments and balanced for cham-
ber, side, floor texture and treatment sequence. During
conditioning sessions, mice were injected with Ex4 (10
g/kg), then, 30 min later, with morphine (10 mg/kg) and
immediately placed in the designated compartment. On
the alternating days, the mice received saline injections
and were placed in the non-drug paired compartment,
with a total of eight once-daily pairings. Control groups
received saline injections paired with both compartments, and
either Ex4 (10 g/kg) or saline pretreatment. This resulted in
four treatment groups: saline saline (SalSal), salinemor-
phine (SalMor), Ex4 saline (Ex4Sal), and Ex4morphine
(Ex4Mor). No injections were given before the pre-con-
ditioning or post-conditioning test sessions. Distance traveled
for locomotor activity and time spent in each compartmentwas
recorded for all sessions.
Operant behaviors
Male Glp1rflox/flox nestin-Cre/ KO and WT mice were
used. To test the efficacy of Ex4 treatment in reducing
opioid self-administration behavior under conditions that
favor acquisition of drug taking, mice were allowed to
acquire nose-poking reinforced with a palatable liquid
food (vanilla flavor Nutridrink), followed by extinction, be-
fore catheter implantation. In addition, to test for general
differences in operant performance between genotypes,
food-reinforced behavior was examined further in a sub-
set of mice.
Food-reinforced operant behaviors
Mice were mildly food restricted starting 6 d before and
until completion of the food-reinforced studies, to no less
than 85% of their free-feeding weight. The liquid food was
first presented in the home cage (5 ml in a plastic cup) 3
d before initiating operant access. Mice were then allowed
to respond under a fixed ratio (FR) 1 timeout 20-s sched-
ule of food reinforcement 5 d/week, as previously de-
scribed (Thomsen et al., 2005) with a few modifications:
session time was shortened to 60 min, and minimum
reinforcers earned to meet criteria were adjusted to 15/
session, and the concentration series was tested only
once. In brief, testing comprised: acquisition (minimum
five sessions and until criteria were met, which was never
more than nine sessions); extinction to 50% of acquisi-
tion reinforcers (minimum three sessions, all met criteria
within three sessions); concentration-response curve
(0%, 3%, 10%, 32%, 100% food in water presented in a
Latin square design). Then, undiluted food was again
available for one session, followed by two consecutive
sessions under a logit-based progressive ratio (PR)
schedule as previously described (Thomsen et al., 2005).
Finally, nose-poking behavior was again extinguished in
at least three sessions under the FR 1 schedule before
catheter implantation. Additional mice used for remifen-
tanil self-administration studies were exposed to the ac-
quisition and extinction phases of the food training only,
with the same criteria.
Catheter implantation and maintenance
The methods of the catheter manufacturing, surgical
implantation, and maintenance have been described in
detail (Thomsen and Caine, 2005; Stoll et al., 2018). In
brief, the catheters consisted of medical-grade silicone
tubing (1-French size; Phymep) attached to a 90°-angled
cannula (Bilaney) fixed in a dental cement base with a
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20-mm disk of polypropylene surgical mesh (Textile De-
velopment Associates). Under sevoflurane anesthesia the
catheter was implanted in the jugular vein and ran sub-
cutaneously to the catheter base located above the mid-
scapular region. The mice were allowed a 7-d recovery
period with daily infusions of 0.03-ml saline containing
heparin (30 USP units/ml) and antibiotics (67-mg/ml ce-
fazolin). The external end of the catheter was kept sealed
outside of self-administration sessions. Catheter patency
was verified by loss of muscle tone and clear signs of
anesthesia within 3 s after the infusion of 0.02- to 0.03-ml
ketamine/midazolam through the catheter (15-mg/ml ket-
amine, 0.75-mg/ml midazolam in saline). Data were only
included when catheter patency was confirmed before
and after completion of an experimental phase.
Remifentanil self-administration
For the self-administration experiment, we chose to
administer Ex4 or saline daily throughout testing, for two
reasons: first, acute effects of candidate medications of-
ten fail to translate to the more clinically relevant effects of
repeated/chronic treatment (Haney and Spealman, 2008;
Czoty et al., 2016), and second, based on the lack of
effect of Ex4 in other assays, we decided to test for
effects on initial remifentanil self-administration. If the
acute reinforcing effects of remifentanil could not be at-
tenuated, it seemed even less likely that well-established
drug taking could be modulated by Ex4.
General self-administration procedures have been de-
scribed in detail (Thomsen and Caine, 2005; Thomsen
et al., 2005), remifentanil doses were based on previous
studies in mice (Caine et al., 2007). Mice were randomly
assigned to either saline or 10-g/kg Ex4 before starting
testing, treatments were administered 30 min before each
session. Mice were allowed to self-administer remifentanil
under an FR 1 timeout 20-s schedule of reinforcement,
5–6 d/week. The dose was first varied individually every
3–4 d based on our experience that this can facilitate
acquisition (Caine et al., 2014), 10- or 32-g/kg/infusion.
Sessions lasted 3 h or until the maximum allowed rein-
forcers were earned, 100 at 10 g/kg and 30 at 32 g/kg.
Mice were considered to self-administer when they took at
least 15 reinforcers per session for two consecutive sessions
with 75% responses in the active hole, on both doses.
Saline was then substituted for remifentanil until responding
decreased to 50% of acquisition reinforcers, followed by
at least one session on the 10-g/kg dose and until re-
sponding increased to the pre-extinction level or re-
stabilized at 15 reinforcers per session, which occurred in
all mice that maintained catheter patency. Response re-
quirement was then increased to FR 3, FR 5, and PR in
successive sessions. Finally, self-administration of 32-g/
kg/infusion remifentanil and of saline were examined under
the PR schedule. Doses were repeated under the PR sched-
ule when catheters were patent long enough, the first and
second determinations did not differ significantly and were
averaged for analysis.
Ethanol self-administration experiment
Male B6 mice were used. Mice were first exposed to
ethanol (20% in water w/v) using a drinking in the dark
procedure (Rhodes et al., 2005), replacing the home cage
water bottles with ethanol solution for 4 h/d for 4 d,
starting 3 h after onset of the dark cycle. Then, ethanol
solution was made available using the same procedure as
the food-reinforced operant responding described above
except that sessions lasted 2 h. After three weeks, mice
that maintained an average consumption of at least 2.5-
g/kg/session ethanol over the last week were considered
“drinkers” and were tested in a counterbalanced se-
quence with saline, 3.2-, and 10-g/kg Ex4, administered
30 min before the session. Test sessions were separated
by at least one baseline session to observe ethanol intake
at pre-testing levels. This experiment was performed con-
currently with remifentanil studies and using the same
batch of Ex4.
Antagonist-precipitated morphine withdrawal
Mice from the CPP experiment plus experimentally na-
ive B6 mice were used. Mice from the CPP experiment
were allowed a 7-d washout period before progressing to
the withdrawal experiment, in which they received the
same treatment as previously (i.e., morphine-exposed
mice remained in a morphine group, etc.). Morphine de-
pendence was induced by 6 d of twice-daily morphine
injections of increasing dose, in the home cage (from 10 to
50 mg/kg). On the test day mice received a last morphine
dose (50 mg/kg) and 2-h later withdrawal symptoms were
precipitated with naltrexone (0.32 mg/kg). Separate co-
horts of mice were used to test the effect of Ex4 (3.2 or 10
g/kg) administered on the test day 30 min before nal-
trexone (testing for effect on expression of withdrawal), or
of repeated Ex4 (10 g/kg) 30 min before each morphine
dose (testing for effect on induction of dependence). Im-
mediately after the naltrexone injection, the mice were
placed individually in clear plastic cylinders and behavior
was video recorded for 30 min, then mice were killed. The
video was analyzed and the number of vertical jumps per
30 min was recorded by an observer blind to treatment
condition.
Hot-plate assay for antinociceptive effect of
morphine
Male and female Glp1rflox/flox nestin-Cre/ KO and WT
mice were used (42 WT males, 51 WT females, 52 KO
males, and 56 KO females, equally distributed between
drug dose groups). Data analysis showed no difference
between the female and male groups; therefore, the data
are presented as sexes combined. Mice were adminis-
tered Ex4 (10 g/kg), followed after 60 min by morphine (5
or 10 mg/kg), and after a further 60 min, the mice were
placed on the hotplate. Nociceptive time latency, defined
as the time required to elicit a hind paw lick or a jump, was
recorded and the animal was removed from the plate. To
minimize the risk of tissue damage, mice were removed if
no response was recorded within 40 s, recording time as
40 s, and mice were killed immediately after the experi-
ment.
Drugs
Morphine hydrochloride, remifentanil hydrochloride (B.
Braun), ketamine hydrochloride (Pfizer), midazolam hydro-
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chloride (Matrix Pharmaceuticals), sevoflurane (AbbVie), ce-
fazoline (MIP Pharma), and heparin (preservative-free, SAD)
were purchased from the Copenhagen University Hospital
Pharmacy. Ex4 was purchased from Tocris Bioscience, and
naltrexone hydrochloride was purchased from Sigma-
Aldrich (product N3136). Alcohol (ethyl alcohol 96% unde-
natured) was purchased from Plum A/S. Doses refer to the
weight of the salts. All drugs were dissolved in sterile saline
(0.9%NaCl), alcohol was diluted in tap water. All drugs were
administered intraperitoneally in a volume of 10 ml/kg, ex-
cept for the twice-daily morphine withdrawal regimen, which
was administered subcutaneously.
Experimental design and statistical analysis
CPP
Time on drug-paired side in pretest and posttest was
analyzed with two-tailed paired-sample t test with Bon-
ferroni correction. The % change in time spent in the
drug-paired compartment between pre-test and posttest
(100 posttest/pretest) was analyzed by ANOVA with
treatment as between-subject factor, followed by Bonfer-
roni posttest. Locomotor activity: distance moved was
analyzed by ANOVA with genotype and Ex4 treatment as
between-subjects factors and consecutive session as
repeated-measures factor. Operant food: reinforcers
earned per session were analyzed by ANOVA with geno-
type as between-subjects factor and consecutive session
number or food concentration as repeated-measures fac-
tor. Operant remifentanil: infusions earned per session
were analyzed by ANOVA with genotype and Ex4 dose as
between-subjects factor and consecutive session num-
ber, or remifentanil dose, or response requirement as
repeated-measures factor. Operant ethanol: g/kg earned
per session was analyzed by ANOVA with Ex4 dose as
repeated-measures factor, followed by Bonferroni post-
test. Withdrawal: jumps per 30 min. were analyzed by
ANOVA with Ex4 treatment, morphine treatment, and nal-
trexone treatment as between-subject factors. In mice
dependent on morphine and challenged with naltrexone,
jumps were analyzed by ANOVA with Ex4 dose as
between-subject factor. Significant effects were followed
by simple effects test (ANOVA) where applicable, then
Bonferroni posttest.
Hot-plate
Due to the cutoff value, hot-plate latency data were not
normally distributed, nor could they readily be trans-
formed into normality, precluding the use of ANOVA.
Latency-to-event data are most appropriately analyzed by
survival statistics (Jahn-Eimermacher et al., 2011). Time
to response was analyzed by Cox proportional hazard
regression with gene, sex, and Ex4 dose as factors; then
re-analyzed with sexes combined as the sex factor never
approached significance. Data had to be analyzed sepa-
rately for each morphine dose to not violate the propor-
tionality assumption.
A priori power analyses were performed using Gpower
2 (Faul et al., 2007) and Stata. For CPP, analysis was
based on the effect sizes reported for acquisition of CPP
using alcohol (Egecioglu et al., 2013c; Vallöf et al., 2016),
both analyses yielding a required n 	 9. For withdrawal
and hotplate no data on GLP-1 analog effects were avail-
able, and a conservative estimate was based on an effect
size of 25% reduction, yielding a required of n 	 11–12.
For self-administration, the primary hypothesis was that
Ex4 would decrease self-administration of remifentanil in
WT mice under an FR 1 schedule of reinforcement, there-
fore analysis was based on the effect size observed for a
relatively high dose of self-administered cocaine (Sø-
rensen et al., 2015) or nicotine (Tuesta et al., 2017) under
FR schedules: both calculations yielded a required n 	 6.
Data were analyzed using GraphPad Prism or Stata, sig-
nificance level was set at p  0.05. All data are presented
as group means  SEM.
Results
CPP and locomotor activity
Place conditioning
CPP, measured as percentage increase in time spent in
the drug-paired compartment (Fig. 1A), was increased by
morphine conditioning relative to saline (F(1,35)	 15.7, p	
0.0004, ANOVA, Bonferroni correction), with no effect of
Ex4 treatment. The time spent on drug-paired side in the
pretest and posttest was also analyzed for each treatment
group and morphine-conditioning produced a significant
place preference in both saline-pretreated mice and Ex4-
pretreated mice (t(9) 	 4.99, p 	 0.0008, paired-sample t
test and t(8) 	 3.26, p 	 0.012, paired-sample t test,
respectively), while saline conditioning had no effect on
place preference.
Locomotor activity
Locomotor activity as distance moved per session was
also recorded during all sessions in the CPP experiment.
Figure 1B shows distance moved during the conditioning
sessions. Morphine increased locomotor activity mark-
edly (F(1102) 	 51.5, p  0.0001, main effect, three-way
ANOVA), with a significant morphine by Ex4 interaction
(F(1102) 	 5.53, p 	 0.02, three-way ANOVA). Ex4 treat-
ment significantly reduced distance moved in the saline-
conditioned groups (F(1,52) 	 7.40, p 	 0.01, two-way
ANOVA followed by Bonferroni posttest), but not did not
significantly modulate morphine-induced locomotor hy-
peractivity (p 	 0.7). Groups did not differ in distance
moved during pre- or post-conditioning test sessions;
similarly, during non-drug conditioning sessions distance
moved remained at 10–20 m/session in all groups (data
not shown).
Operant behaviors
Food-reinforced operant behaviors
Male GLP-1 receptor nestin-Cre KO and WT mice were
allowed to acquire nose-poking reinforced with liquid
food (Fig. 2A). Food was then replaced with water (Fig.
2B), then a series of food reinforcer dilutions were pre-
sented (Fig. 2C). Finally, undiluted food was made avail-
able under a PR schedule of reinforcement for two
sessions (shown averaged, Fig. 2D). The two genotypes
did not differ significantly in any behaviors under the FR 1
schedule of reinforcement: reinforcers earned increased
as a function of number of acquisition sessions (F(4148) 	
59.1, p  0.0001) and decreased as a function of extinc-
Negative Results 5 of 17
March/April 2019, 6(2) e0443-18.2019 eNeuro.org
tion sessions (F(2,73) 	 148.1, p  0.0001), and reinforcers
earned varied as a function of food concentration (F(4148)
	 111.7, p  0.0001), with no effect of genotype or
interactions with genotype (all main effect, two-way
ANOVA). When tested under an increased response re-
quirement, the KO mice reached higher breaking points
(more reinforcers earned) than the WT mice (F(1,37)	 7.01,
p 	 0.01, one-way ANOVA).
Remifentanil self-administration
Saline-treated or Ex4-treated (10 g/kg) KO and WT
groups did not differ in the rate of acquisition or number of
remifentanil reinforcers earned under acquisition. How-
ever, there was a tendency for Ex4-treated WT mice to
increase responding to acquisition level following extinc-
tion (“rebaseline”) more rapidly and to a higher intake
relative to saline-treated WT mice. This observation was
supported statistically by a significant genotype by treat-
ment interaction (F(1,47) 	 6.99, p 	 0.01, three-way
ANOVA) on remifentanil reinforcers (or saline infusions)
earned per session at acquisition criteria, extinction crite-
ria, and on the first and last (	 criteria) session of rebase-
line (Fig. 3A), although post hoc comparisons did not
reach significance. Reinforcers earned were also related
to training phase (F(3,47) 	 24.4, p  0.0001, main effect,
three-way ANOVA), with no other significant interactions.
Self-administration behavior was related to remifentanil
dose under the FR 1 schedule of reinforcement (F(2,46) 	
45.7, p  0.0001, main effect, three-way ANOVA) with
highest intake at 10 g/kg/infusion remifentanil, regard-
less of treatment and genotype (overall Bonferroni post-
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test vs saline, 10-g/kg/infusion, p  0.001, 32-g/kg/
infusion, p 	 0.007; Fig. 3B).
When the response requirement to earn infusions of 10
g/kg/infusion remifentanil was increased in successive
sessions in a smaller number of mice, behavior was
marked by great variability due to one to two mice in all
groups defending their intake (i.e.,20 reinforcers earned
under the FR 5 schedule) but most mice decreasing intake
steeply. Overall, reinforcers earned decreased as a func-
tion of cost (F(2,20) 	 5.64, p 	 0.01, main effect, three-
way ANOVA; FR 3, p	 0.050 Bonferroni posttest vs FR 1;
FR 5, p 	 0.02 vs FR 1; Fig. 4A) with no other factors or
interactions approaching significance. Although not
enough to maintain intake levels, mice did increase active
responses as a function of cost (F(2,20) 	 4.13, p 	 0.03,
main effect, three-way ANOVA; none significant post hoc;
Fig. 4B). Again, the tendency was for Ex4-treated WT
mice to earn more remifentanil reinforcers and emit more
responses relative to saline-treated WT mice. Finally, 10-
and 32-g/kg/infusion remifentanil and saline were made
available under the PR schedule of reinforcement, data
were again marked by variability due to the same one to
two mice in each group showing high intake. Reinforcers
earned (F(2,24) 	 4.78, p 	 0.02; Fig. 4C) and total active
responses (F(2,24) 	 4.41, p 	 0.02; Fig. 4D) were related
to remifentanil dose only (main effects, three-way
ANOVA).
Ethanol self-administration experiment
Using the same operant conditioning chambers and the
same batch of Ex4, concurrently with the remifentanil
IVSA studies, we confirmed that Ex4 can decrease re-
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Figure 3. Remifentanil IVSA under an FR 1 schedule of reinforcement. Reinforcers earned per 3-h session in saline-treated and
Ex4-treated WT mice and in saline-treated and Ex4-treated KO mice. A, Reinforcers earned at acquisition criteria (Acqui., 10-g/
kg/infusion remifentanil), at extinction criteria (Ext., saline), on the first day of post-extinction self-administration rebaseline (Reb1) and
at rebaseline criteria (Reb.). Ex4 treatment appeared to increase remifentanil self-administration in the WT mice, supported by a
significant genotype by treatment interaction. B, Reinforcers earned as a function of remifentanil unit dose (g/kg/infusion); reinforcers
were significantly related to dose but not to genotype or Ex4 treatment. KO, n 	 5–7; WT, n 	 6–7.
Figure Contributions: Annika Billefeld Bornebusch and Saiy Kiasari collected the data. Morgane Thomsen designed the experiments.
Annika Billefeld Bornebusch and Morgane Thomsen analyzed the data.
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sponding maintained by oral ethanol under an FR 1
schedule of reinforcement (F(3,18) 	 5.52, p 	 0.007,
one-way ANOVA; Fig. 5), both at 3.2 g/kg (p 	 0.04,
Bonferroni posttest vs baseline) and at 10 g/kg (p 	
0.02).
Antagonist-precipitated morphine withdrawal
The somatic symptoms of morphine withdrawal were
measured as jumps per 30 min. and are shown in Figure
6, the control data for mice receiving saline during acqui-
sition and expression are shown pooled. There was a
significant interaction of morphine and naltrexone treat-
ment (F(1,87)	 34.2, p 0.001, three-way ANOVA), induc-
ing morphine withdrawal and jumping. In the morphine-
dependent groups treated with naltrexone there was no
significant effect of Ex4 treatments (p 	 0.2, one-way
ANOVA; Fig. 6A). There was also no significant effect of
Ex4 treatment in the non-withdrawal control groups (Fig.
6B).
Antinociceptive effect of morphine
Hot-plate latencies were analyzed for each morphine
dose and are shown in Figure 7. Sex was never a signif-
icant factor; therefore, data are reported as sexes com-
bined. After administration of saline (Fig. 7A) or 5-mg/kg
morphine (Fig. 7B), latency to nociceptive response was
not significantly related to genotype or Ex4 condition. At
10-mg/kg morphine, there was a significant effect of Ex4
treatment (p	 0.045, Cox proportional hazard regression)
and significant genotype by Ex4 interaction (p  0.001;
Fig 7C), while the main effect of genotype approached
significance (p 	 0.075). The interaction reflected that the
Ex4 effect approached significance to reduce latency in
the WT mice (p 	 0.054) but not in the KO mice (p 	 1.0).
Discussion
Our findings in the present study indicate that GLP-1
receptor agonists do not reduce abuse-related effects of
opioids in assays of reward, reinforcement, or withdrawal,
as well as morphine-induced hyperactivity.
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Morphine produces place preference in the CPP assay,
which is related to the perception of opioid reward (Bardo
and Bevins, 2000). GLP-1 receptor agonists have been
shown to block or reduce CPP conditioned by alcohol,
cocaine, amphetamine, and nicotine (Egecioglu et al.,
2013a, b,c; Graham et al., 2013; Shirazi et al., 2013;
Harasta et al., 2015; Vallöf et al., 2016; Sirohi et al., 2016).
In contrast, we found that Ex4 pretreatment did not alter
acquisition of morphine-conditioned CPP, despite using a
moderately high dose (10 g/kg) compared to 2.4-g/kg
Ex4 being sufficient to prevent acquisition and/or expres-
sion of CPP in previous studies (Egecioglu et al., 2013a,
b,c; Sirohi et al., 2016). The doses used in the present
investigation were based on preliminary studies showing
no effect of lower doses Ex4 with morphine (data not
shown), and 10 g/kg was selected as the highest dose
that would not induce side effects to a degree that would
interfere with interpretation of the data. Indeed, 10-g/kg
Ex4 by itself produced significant decreases in locomotor
activity during the conditioning sessions, relative to saline.
This effect is consistent with previous findings (Krass
et al., 2012; Sørensen et al., 2015) and confirms that the
Ex4 treatment used was “active” in these investigations. A
dose of 10-g/kg Ex4 alone did not produce conditioned
place aversion, indicating that aversive effects of the Ex4
treatment at the doses used in our study are unlikely to
contribute significantly to the behavioral outcomes ob-
served.
We also tested whether Ex4 treatment would decrease
the reinforcing effects of an opioid drug, i.e., active drug
taking behavior. Ex4 did not attenuate the reinforcing
properties of remifentanil in WT mice during acquisition,
extinction, rebaseline, or FR 1 dose-response testing. A
smaller number of animals were also tested under in-
creased response requirement conditions. If anything, the
tendency for Ex4 to increase remifentanil self-admini-
stration under the post-extinction rebaseline and in-
creased response requirement conditions would suggest
an increased reinforcing effect of remifentanil. This is
again in contrast to other addictive substances: GLP-1
receptor agonists decreased IVSA of alcohol, cocaine,
and nicotine (Sørensen et al., 2015, 2016; Schmidt et al.,
2016; Tuesta et al., 2017) and oral self-administration of
alcohol (Egecioglu et al., 2013c; Vallöf et al., 2016). Im-
portantly, we confirmed that 3.2- and 10-g/kg Ex4 sig-
nificantly decreased oral alcohol self-administration in
mice under the same experimental conditions as our
remifentanil IVSA studies.
The IVSA experiment included mice lacking GLP-1 re-
ceptors specifically in the central nervous system but
expressing GLP-1 receptors in peripheral tissues. Per-
haps not surprisingly in light of the lack of effect of Ex4
treatment, we found no difference in IVSA behavior be-
tween WT and KO mice. The exception was a genotype
by treatment interaction during post-extinction rebase-
line, suggesting that Ex4 increased remifentanil IVSA in
the WT mice but not in the KO mice, consistent with an
effect mediated through central GLP-1 receptors. A trend
for higher responding under the PR schedule of reinforce-
ment in the KO mice was most likely not drug-specific,
because KO mice reached significantly higher breaking
points than WT mice when tested with food. The consti-
tutive lack of GLP-1 receptors may lead to an increased
responsiveness to positive reinforcers generally. Indeed,
similar to genetic ablation, systemic or intracranial admin-
istration of a GLP-1 receptor antagonist can increase
intake of sucrose, fat, and alcohol, and increased
sucrose-reinforced responding under a PR schedule in
rats (Knauf et al., 2008; Shirazi et al., 2013; Terrill et al.,
2016). Behavior under increased response requirement
was marked by strong variability, which may be related to
the mixed genetic background (129, SJL and back-
crossed to C57BL/6J) or to the nestin-Cre manipulation
rather than GLP-1 receptor genotype. For this reason, i.e.,
the possibility of confounding genetic factors, and be-
cause there was no indication that Ex4 would decrease
remifentanil IVSA with higher group sizes, we decided
against operating and training additional animals for test-
ing under the PR schedule, since there was no clear
benefit to counter the ethical and resource costs.
In humans, opioid drugs produce physical dependence
that contributes heavily to continued drug use (Weiss
et al., 2014). In rodents, opioids similarly induce de-
pendence-like behaviors after a few exposures, as de-
fined by withdrawal symptoms being precipitated by
administration of a mu opioid receptor antagonist or by
abrupt cessation of opioid treatment (Schulteis et al.,
1997). We tested whether Ex4 could prevent the induction
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Figure 5. Ethanol self-administration experiment. Ethanol intake
(g/kg/2-h session) as a function of Ex4 dose (g/kg) or baseline
intake (B). As a direct comparison, the effect of Ex4 on operant
behavior reinforced with oral ethanol solution was assessed,
under an FR 1 schedule of reinforcement. Both Ex4 doses
decreased ethanol intake significantly; p  0.05 versus baseline;
n 	 7–9.
Figure Contributions: Annika Billefeld Bornebusch and Saiy Ki-
asari collected the data. Morgane Thomsen designed the exper-
iments. Annika Billefeld Bornebusch analyzed the data.
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of dependence-like behavior and/or the expression of
withdrawal symptoms. Neither administration of Ex4 dur-
ing induction of dependence nor administration of Ex4 on
the test day decreased the severity of withdrawal symp-
toms. In mice, morphine also produces hyperlocomotion,
which was also not attenuated by Ex4, measured during
the conditioning sessions of the CPP experiment, despite
decreasing spontaneous (saline) locomotor activity. Taken
together, GLP-1 receptor agonist treatment, acute or sub-
chronic, was ineffective at decreasing opioid reward, re-
inforcement, or dependence/withdrawal, even at doses
higher than those needed to significantly disrupt abuse-
related behavioral and biochemical effects of alcohol,
stimulants, and nicotine.
Finally, we tested whether Ex4 treatment would alter
the analgesic effects of morphine. Ex4 did not produce an
analgesic or hyperalgesic effect in itself in the hot-plate
test. While Ex4 has shown antinociceptive effects in hy-
persensitivity models, our lack of effect on acute pain
perception is consistent with previous reports (Möller
et al., 2002; Gong et al., 2014). Ex4 treatment tended to
reduce the effect of morphine in the hot-plate test in WT
mice, but because most mice reached the cutoff time,
making statistical power weaker, it is difficult to conclude
based on those data. A possible interaction between
GLP-1 agonists and morphine in analgesia tests may be
worth investigating further.
Because GLP-1 receptor agonists have been shown to
attenuate abuse-related effects of alcohol, central stimu-
lants (cocaine and amphetamine), and nicotine in rats and
mice, it seems surprising that Ex4 had no attenuating
effect on the abuse-related effects of morphine or
remifentanil in the present investigation. This apparent
discrepancy is not easily explained by differences in li-
gand (Ex4 is the most thoroughly tested agonist with other
drugs of abuse), species, strain, sex, type of assay, acute
versus chronic dosing, dose range, ligand formulation, or
even laboratory/experimenter. Rather, this difference
likely informs the mechanism of action of GLP-1 receptor
agonists on reward pathways, which are still poorly un-
derstood. Studies using direct infusion of GLP-1 receptor
agonists into the brain, KO mice lacking GLP-1 receptors
in specific tissues, or chemogenetic stimulation of spe-
cific cell populations converge to strongly indicate that
reduced intake of alcohol, central stimulants, and nicotine
depend on GLP-1 receptor stimulation in the brain, rather
than in peripheral tissues (Shirazi et al., 2013; Harasta
et al., 2015; Sirohi et al., 2016; Tuesta et al., 2017; Her-
nandez et al., 2019). These studies have pointed to brain
areas known to be important for reward/addiction and
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Figure 6. Antagonist-precipitated morphine withdrawal. Somatic withdrawal symptoms measured as jumps per 30 min. A, In mice
made dependent with daily morphine injections and challenged with naltrexone (0.32 mg/kg) on the test day, naltrexone precipitated
withdrawal symptoms in all groups, with no significant effect of Ex4 administration either as daily pretreatment to morphine
(acquisition of morphine dependence; 3.2 and 10 g/kg) or on the test day (expression of withdrawal; 10 g/kg), relative to mice
treated with saline (control). Control data are shown pooled for mice receiving saline during acquisition or expression. B, Control
groups treated with saline and naltrexone, saline-saline, or morphine-saline did not show withdrawal symptoms and showed no effect
of Ex4 treatments. Data are group mean  SEM as well as all individual points; A, n 	 7–22; B, n 	 1–14.
Figure Contributions: Annika Billefeld Bornebusch collected the data. Morgane Thomsen designed the experiments. Annika Billefeld
Bornebusch and Morgane Thomsen analyzed the data.
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that express GLP-1 receptors at low to moderate levels
(NAc, VTA), as well as to areas enriched in GLP-1 recep-
tors and whose roles in addiction or reward and recently
being (re)discovered (lateral septum, interpeduncular nu-
cleus) as possible targets for the GLP-1 analogs (Shirazi
et al., 2013; Harasta et al., 2015; Reddy et al., 2016;
Schmidt et al., 2016; Tuesta et al., 2017; Abtahi et al.,
2018; Hernandez et al., 2018, 2019). How the apparent
effects of GLP-1 receptor stimulation in those various
brain regions are related at a circuit level and how the
effects are mediated at the neuronal or molecular level
remains to be elucidated. However, no obvious drug class
separation emerges from this picture, since VTA, NAc,
and lateral septum have also been implicated in the
addiction-related effects of opioids (Le Merrer et al., 2007;
Fields and Margolis, 2015; Jiang et al., 2018; but see
Perrotti et al., 2008 on differential 
FosB expression in
lateral septum).
In particular, disinhibition/stimulation of dopaminergic
neurons in the relatively heterogeneous region commonly
referred to as the VTA are thought to play a critical role in
the reinforcing effects of alcohol, nicotine, and opioids.
Recent evidence indicates that stimulation of GLP-1 re-
ceptors in the VTA weakens synaptic strength of VTA-NAc
projections in mice (Wang et al., 2015b), which is probably
downstream of the effects of alcohol, nicotine, and opi-
oids on VTA neurons. Studies in rats indicated that GLP-1
receptor stimulation in the VTA could increase dopami-
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Figure 7. Antinociceptive effect of morphine. Latencies in seconds to nociceptive response in male and female GLP-1 receptor
nestin-Cre KO and WT mice tested on a 55°C hot-plate after pretreatment with saline or Ex4 (10 g/kg) and administration of (A)
saline, (B) 5-mg/kg morphine, or (C) 10-mg/kg morphine, with a cutoff at 40 s. Data are shown as the % of mice showing a response
as a function of time. Latencies did not differ significantly by genotype or Ex4 treatment for saline or 5-mg/kg morphine. For 10-mg/kg
morphine, there was a genotype by Ex4 interaction and a trend for reduced latency in the Ex4-treated WT mice relative to saline but
not in the KO mice; n 	 11–14 (morphine doses) and n 	 23–27 (saline, combined from both dose cohorts).
Figure Contributions: Annika Billefeld Bornebusch and Gitta Wörtwein collected the data. Morgane Thomsen and Annika Billefeld
Bornebusch designed the experiments and analyzed the data.
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nergic neuron activity via a presynaptic mechanism
(Mietlicki-Baase et al., 2013). Apart from species and
methodological differences between the two studies, this
apparent discrepancy illustrates the complexity of GLP-1
receptor actions in the central nervous system at the
synaptic level, which include both inhibitory and stimula-
tory effects, sometimes within the same structure (for
review, see Liu and Pang, 2016). Relatively few VTA neu-
rons express GLP-1 receptors (Cork et al., 2015; Harasta
et al., 2015), and rewarding and aversive stimuli including
opioids and other drugs may inhibit and stimulate differ-
ent populations of dopaminergic VTA neurons (Lammel
et al., 2011, 2012; Fields and Margolis, 2015). It is there-
fore possible that GLP-1 receptors are only expressed on
neuron populations that are modulated preferentially by
some drugs. To understand how GLP-1 systems influence
reward and addiction, it will be important to better identify
the neuron populations that express GLP-1 receptors,
and the synaptic and cellular effects of GLP-1 receptor
stimulation in specific pathways.
At the behavioral level, GLP-1 receptor stimulation may
reduce appetitive effects of alcohol, central stimulants, and
nicotine, or may enhance effects that limit intake, such as
aversion and/or satiety, or both. For instance, Tuesta et al.,
(2017) suggested that stimulation of GLP-1 receptors in the
medial habenula-interpeduncular nucleus circuit decreases
nicotine intake by modulating nicotine satiety. Similarly, self-
administered cocaine was suggested to produce a GLP-1-
dependent negative-feedback loop through activation of
stress circuits including corticosterone, limiting cocaine in-
take (Schmidt et al., 2016), which could also be interpreted
as a form of GLP-1-potentiated cocaine “satiety.” Such
mechanisms would be in line with the well-established role
of GLP-1 circuits to regulate nutrient intake. In this re-
spect, it is unclear how opioids may differ from other drug
classes in “satiating” or aversive effects. Some authors
argue that, at least in the acquisition of drug taking stage,
opioids produce an almost pure euphoric (approach) re-
sponse in humans and rodents, while cocaine produce
mixed euphoric/aversive (approach/avoidance) effects
(Badiani et al., 2011). However, this difference between
cocaine and heroin in approach/avoidance behavior is
most likely pharmacokinetic, with the shorter-acting co-
caine producing euphoric and aversive (“crash”) effects in
closer temporal proximity relative to heroin, D-amphe-
tamine, or methamphetamine (Ettenberg, 1990, 2004,
2009; Akhiary et al., 2018). Mixed appetitive/aversive ef-
fects can be observed for all major classes of abused
drugs including opioids, in humans and laboratory ani-
mals (Angst et al., 2012; Verendeev and Riley, 2013).
Nevertheless, is it possible that GLP-1 receptor stimula-
tion decreases drug taking and drug seeking by potenti-
ating some aversive or satiating effects of alcohol,
stimulants, and nicotine that are not shared by opioids.
For instance, rewarding versus aversive effects of opioids
may be more distinctly dependent on central versus pe-
ripheral mechanisms (Bechara and van der Kooy, 1985). It
would be useful to better understand the nature of GLP-
1-mediated modulation of drug taking and alcohol taking
and seeking behaviors, in terms of satiety, motivation,
craving, direct reinforcing and aversive/punishing strength, and
salience of conditioned reinforcers/punishers associated with
drug/alcohol taking.
Regarding the possible involvement of stress systems
(cf. Schmidt et al., 2016), corticotropin-releasing factor
(CRF)-releasing neurons in the hypothalamus express
GLP-1 receptors, and GLP-1 receptor stimulation in-
creases CRF signaling (Larsen et al., 1997; Kinzig et al.,
2003; Ghosal et al., 2017; Liu et al., 2017). However, at the
systemic level, activation of stress systems likely contrib-
utes to addictive effects or drugs more than it opposes
them, at least in the later stages of addiction (for review,
see Koob, 2008; Koob and Volkow, 2016), making it
difficult to speculate on the role of GLP-1-mediated CRF
release in “anti-addictive” effects. Moreover, GLP-1-
mediated increases in CRF or corticotropin levels do not
offer an obvious explanation for why GLP-1 receptor ago-
nists attenuate effects of alcohol, stimulants, and nicotine,
but not opioids. Indeed, activation of stress systems,
including increased levels of CRF, are observed with
chronic use of alcohol, stimulants, nicotine, and opioids,
and CRF antagonists can reduce effects of chronic opioid
exposure including drug seeking and withdrawal symp-
toms, similar to effects observed with other drug classes
(Shaham et al., 1998; Stinus et al., 2005; Park et al., 2015;
for review, see Koob, 2008). While most studies have
measured acute effects of GLP-1 receptor agonists,
GLP-1 agonist treatment can also attenuate effects of
alcohol in more chronic experimental designs, when stress
systems are presumably in play. GLP-1 receptor agonists
appeared to attenuate ethanol withdrawal symptoms and
craving, based on measures of anxiety-like behavior and
alcohol deprivation-induced drinking (Sharma et al., 2015;
Vallöf et al., 2016; Thomsen et al., 2017). GLP-1 agonists
reduced alcohol intake in non-human primates with many
months history of drinking (Thomsen et al., 2018), and one
GLP-1 analog was effective in decreasing drinking only in
mice with repeated exposure to ethanol and presumed to
have developed ethanol dependence (Suchankova et al.,
2015). Taken together, activation of stress systems does not
seem a likely general mechanism by which GLP-1 receptor
agonists decrease drug seeking and drug taking.
We hypothesize that GLP-1 receptor agonists may ef-
fectively attenuate abuse-related effects that are specifi-
cally dependent on striatal dopamine D1 receptor (Drd1)
pathway signaling. There is strong evidence that alcohol,
central stimulants, and nicotine all produce addictive ef-
fects dependent on Drd1-dependent mechanisms. Rein-
forcing and rewarding effects of alcohol, cocaine, and
nicotine can be attenuated by blocking/decreasing Drd1
pharmacologically or genetically, and blockade in the nu-
cleus accumbens shell appears sufficient to produce at
least some of those effects (Corrigall and Coen, 1991;
David et al., 2006; Bahi and Dreyer, 2012; Young et al.,
2014; Ding et al., 2015; Pisanu et al., 2015). The same
manipulations did not impair the reinforcing effects of
heroin in a direct comparison (Pisanu et al., 2015). Studies
using KO mice further support differences between alco-
hol or stimulants versus opioids. KO mice lacking Drd1
receptors showed no reinforcing effects of cocaine and
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strongly reduced alcohol drinking, but showed normal
remifentanil self-administration and normal morphine CPP
(El-Ghundi et al., 1998; Caine et al., 2007; Urs et al., 2011;
Ting-A-Kee et al., 2013). Conversely, KO mice lacking
Drd2 receptors failed to self-administer morphine and
failed to develop morphine CPP or morphine withdrawal-
conditioned aversion, but self-administered cocaine to
overdose and showed normal cocaine CPP (Caine et al.,
2002; Elmer et al., 2002; Smith et al., 2002). Opioids and
other drug classes also produce qualitatively different
adaptations of Drd1-expressing and Drd2-expressing
medium spiny neurons (MSNs) at the molecular level.
Cocaine, alcohol, and tetrahydrocannabinol all induce

FosB specifically in Drd1-expressing MSNs, whereas
morphine and heroin induce 
FosB in both Drd1 and
Drd2-expressing MSNs (Kelz et al., 1999; Lobo et al.,
2013; see also Wang et al., 2015a). Acute effects of
opioids may involve Drd1-dependent mechanism, but af-
ter chronic exposure and cycles of dependence and with-
drawal, the mechanism appears to switch to more Drd2-
dependent mechanisms (Georges et al., 2000; Lintas
et al., 2011; Enoksson et al., 2012). In contrast, cocaine
affects both Drd1-and Drd2-expressing neurons acutely,
albeit in different ways (Bertran-Gonzalez et al., 2008; Luo
et al., 2011), but repeated administration appears to shift
effects toward Drd1-expressing neurons almost exclu-
sively (Lee et al., 2006; Bertran-Gonzalez et al., 2008). For
instance, cocaine-induced increases in dendritic spine
density occurs in Drd1 and Drd2 MSNs, but is maintained
long-term only in Drd1 MSNs (Lee et al., 2006). Thus
cocaine and morphine may produce addictive effects by
producing similar shifts in the balance between Drd1 and
Drd2 MSNs activity but through different mechanisms,
one modulating Drd1 neurons, the other, Drd2 neurons
(Koo et al., 2014; Graziane et al., 2016; Renteria et al.,
2017). It is not known whether Drd1/Drd2 subpopulations
of MSNs are affected differentially by GLP-1 manipula-
tions, but recent studies indicate that Ex4 can modulate
MSNs excitability in cocaine-experienced but not drug-
naive rats, and that this response was observed only in
roughly half the recorded MSNs (Hernandez et al., 2019).
The shift from acute drug effects to addiction and/or
dependence is accompanied by neuroplasticity changes
in the brain. While many such changes are observed
across drug classes, such as altered glutamatergic trans-
mission and redistribution of AMPA receptors (Saal et al.,
2003; Brown et al., 2010), there also are important differ-
ences. For instance, self-administration of opioids but not
cocaine, alcohol, or nicotine was observed to cause mor-
phologic changes in dopaminergic VTA neurons (Mazei-
Robison et al., 2014). Chronic self-administration of
and/or passive exposure to cocaine, amphetamine, or
nicotine increases dendritic spine density in NAc MSNs
and in prefrontal cortex, while morphine exposure under
comparable experimental conditions decreases dendritic
spine density, and alcohol produces more complex alter-
ations in spine morphology (Brown and Kolb, 2001; Rob-
inson et al., 2001, 2002; Zhou et al., 2007; Uys et al., 2016;
for review, see Robinson and Kolb, 2004; Russo et al.,
2010). It is unclear whether such differences in the mal-
adaptive changes to chronic drug exposure can explain
the lack of effect of Ex4 on acute effects of opioids (as
well as repeated-exposure effects) in the present study,
although neuroplasticity changes may begin to form after
one or a few drug exposures. In elucidating how GLP-1
receptor stimulation modulates addictive effects of alco-
hol or drugs, it would be informative to examine the
effects of GLP-1 analog treatments on neuroplasticity
changes such as spine/neuron morphology and gluta-
mate receptor characteristics.
In conclusion, unlike other addictive substances inves-
tigated so far, Ex4 did not attenuate the addiction-related
behavioral effects of opioids in mice, and we found no
indication that GLP-1 analogs would have a beneficial
effect in the medical treatment of opioid dependence.
This difference between opioids and other drug classes
may shed light on the mechanism of action of GLP-1
receptor treatment in the addictive effects of alcohol,
central stimulants, and nicotine.
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